Earli programs cancer against itself, using AI-designed genetic switches that tell malignant cells to reveal themselves and make their own therapies.
Products & media
Cancer-Activated Gene Expression Platform
An investigational platform using AI-designed genetic switches and targeted nanoparticles to make cancer cells produce detectable biomarkers or immune therapies.
Cosigns
Vinod KhoslaFounder at Khosla Ventures
“We believe Earli has the potential to forever change the cancer playbook.”
Cyriac RoedingCo-founder and CEO of Earli; entrepreneur and investor focused on biotechnology, consumer technology, and frontier innovation.
“We bring together people that don’t traditionally interact at other companies like biologists, chemists, engineers, and computer scientists.”
Team
Founders
2 people
Jobs
Funding
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels